Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

April 30, 2024

https://www.globenewswire.com/news-release/2024/04/30/2872162/0/en/Processa-Pharmaceuticals-Names-Dr-Steven-Cha-Senior-Vice-President-of-Clinical-Research.html

Brings extensive experience in all phases of oncology drug development

HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) (Processa or the Company), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, today announced that it has named Steven Cha, M.D. as Senior Vice President of Clinical Research. In this newly created position, Dr. Cha’s experience as an oncologist as well as in oncology drug development will be important additions to Processa.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.